Impact Biomedical Acquires Celios

 Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced the acquisition of Celios®, a pioneering air purification technology company, in a strategic, all equity transaction valued at approximately $1.15 million. This acquisition aligns with Impact Biomedical’s focused roll-up strategy, expanding its portfolio with cutting-edge solutions that will generate immediate revenue while reinforcing its commitment to human health and wellness.

https://www.globenewswire.com/news-release/2025/02/26/3032920/0/en/Impact-Biomedical-Inc-Announces-Acquisition-of-Celios-Protecting-People-Plants-and-Animals-from-the-World-s-Most-Dangerous-Pathogens-With-Clean-Room-Air-Quality.html